Crizotinib for recurring non‐small‐cell lung cancer with EML4‐ALK fusion genes previously treated with alectinib: A phase II trial

समान संसाधन

• Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
  द्वारा: Isozaki, Hideko, और अन्य
  प्रकाशित: (2015)
• A phase I/II trial of weekly nab‐paclitaxel for pretreated non‐small‐cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement
  द्वारा: Harada, Daijiro, और अन्य
  प्रकाशित: (2019)
• The Role of STAT3 in Non-Small Cell Lung Cancer
  द्वारा: Harada, Daijiro, और अन्य
  प्रकाशित: (2014)
• Alectinib treatment response in lung adenocarcinoma patient with novel EML4‐ALK variant
  द्वारा: Song, Peng, और अन्य
  प्रकाशित: (2018)
• Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
  द्वारा: Fontana, Diletta, और अन्य
  प्रकाशित: (2015)